Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue.

skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Healthcare Professional Verification

This section contains medical information for licensed healthcare professionals only. Please confirm your professional status to continue.

From Bench to Bedside: anti-MCV as a Marker in Rheumatoid Arthritis – Podcast

Our commitment to enabling early and accurate diagnosis of Rheumatoid Arthritis (RA) remains one of our top priorities, driven by innovative, high-quality diagnostic solutions designed to support better patient outcomes.

By offering a reliable and clinically validated anti-MCV assay, we support healthcare professionals in identifying RA with high specificity, enabling earlier intervention and improved patient management.

In this podcast, powered in partnership with Medlab Middle East, we explore the evolving landscape of autoimmune diagnostics and innovation, with a focus on anti-MCV as a key marker of RA.

This webinar is presented in English.

Published: 4/30/2025 | Modified: 8/7/2026

What will you learn?

  • The role of Anti-MCV in early rheumatoid arthritis diagnosis

    Discover how Anti-MCV helps identify rheumatoid arthritis earlier, especially in patients who test negative for conventional biomarkers, enabling faster treatment and better outcomes.

  • From scientific discovery to clinical practice

    Learn how collaboration between researchers, clinicians, and diagnostic companies transformed Anti-MCV into a globally adopted biomarker, and the key challenges of bringing innovation to routine care.

  • The future of autoimmune diagnostics and precision medicine

    Explore how advanced biomarkers, earlier detection, risk prediction, and personalized therapies are shaping the next generation of autoimmune disease management and improving patient care.

The earlier you diagnose a patient, the earlier you can intervene therapeutically
Dr.. Oliver SENDSCHEID Senior Director Strategy & Innovation, Sebia

About Dr. Oliver SENDSCHEID

Dr. Oliver Schenside leads Sebia's global Autoimmunity business, driving the development and adoption of innovative diagnostic solutions. With extensive experience in product management, scientific affairs and autoimmune diagnostics, he is passionate about translating scientific innovation into clinical practice to improve patient outcomes worldwide.
Dr. Oliver SENDSCHEID

Test associated with this resource

Deepen your expertise with additional webinars

This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.